OA13294A - Molécules duales contenant un dérivé peroxydique, leur synthèse et leurs applications thérapeutiques. - Google Patents

Molécules duales contenant un dérivé peroxydique, leur synthèse et leurs applications thérapeutiques. Download PDF

Info

Publication number: OA13294A
Authority: OA; OAPI
Prior art keywords: formula; mmol; molecules according; radical; trioxaquine
Prior art date: 2000-04-06

Application number

OA1200200308A

Other languages

English (en)

French (fr)

Inventor

Bernard Meunier

Anne Robert

Odile Dechy-Cabaret

Francoise Benoit-Vical

Original Assignee

Centre Nat Rech Scient

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-06

Filing date

2001-04-04

Publication date

2007-04-13

2001-04-04 Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient

2007-04-13 Publication of OA13294A publication Critical patent/OA13294A/fr

Links

230000009977 dual effect Effects 0.000 title claims abstract description 13
230000015572 biosynthetic process Effects 0.000 title description 16
238000003786 synthesis reaction Methods 0.000 title description 16
230000001225 therapeutic effect Effects 0.000 title description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 64
-1 cyclic peroxide Chemical class 0.000 claims abstract description 51
230000008878 coupling Effects 0.000 claims abstract description 27
238000010168 coupling process Methods 0.000 claims abstract description 27
238000005859 coupling reaction Methods 0.000 claims abstract description 27
230000000078 anti-malarial effect Effects 0.000 claims abstract description 18
239000003814 drug Substances 0.000 claims abstract description 11
239000002253 acid Substances 0.000 claims abstract description 9
229940079593 drug Drugs 0.000 claims abstract description 9
150000001412 amines Chemical class 0.000 claims abstract description 7
150000003839 salts Chemical class 0.000 claims abstract description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 6
150000001408 amides Chemical class 0.000 claims abstract description 5
229940124530 sulfonamide Drugs 0.000 claims abstract description 5
150000003568 thioethers Chemical group 0.000 claims abstract description 5
150000007513 acids Chemical class 0.000 claims abstract description 4
125000006833 (C1-C5) alkylene group Chemical group 0.000 claims abstract description 3
125000003367 polycyclic group Chemical group 0.000 claims abstract description 3
150000002576 ketones Chemical class 0.000 claims description 40
239000000203 mixture Substances 0.000 claims description 38
125000001424 substituent group Chemical group 0.000 claims description 25
150000001875 compounds Chemical class 0.000 claims description 21
KQBSGRWMSNFIPG-UHFFFAOYSA-N trioxane Chemical compound C1COOOC1 KQBSGRWMSNFIPG-UHFFFAOYSA-N 0.000 claims description 14
238000006243 chemical reaction Methods 0.000 claims description 13
238000006268 reductive amination reaction Methods 0.000 claims description 13
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 11
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 9
239000004480 active ingredient Substances 0.000 claims description 9
229910001882 dioxygen Inorganic materials 0.000 claims description 9
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
239000000243 solution Substances 0.000 claims description 9
150000004901 trioxanes Chemical class 0.000 claims description 8
125000004122 cyclic group Chemical group 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
125000005843 halogen group Chemical group 0.000 claims description 6
150000005010 aminoquinolines Chemical class 0.000 claims description 5
201000004792 malaria Diseases 0.000 claims description 5
150000003456 sulfonamides Chemical class 0.000 claims description 5
239000003826 tablet Substances 0.000 claims description 5
150000005840 aryl radicals Chemical class 0.000 claims description 4
WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 claims description 4
229960000611 pyrimethamine Drugs 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
239000000725 suspension Substances 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
125000004429 atom Chemical group 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
150000004985 diamines Chemical class 0.000 claims description 3
125000005594 diketone group Chemical group 0.000 claims description 3
239000000839 emulsion Substances 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
125000004430 oxygen atom Chemical group O* 0.000 claims description 3
239000003504 photosensitizing agent Substances 0.000 claims description 3
125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
HAFQHNGZPQYKFF-UHFFFAOYSA-N 1,3,3a,4,6,6a-hexahydropentalene-2,5-dione Chemical compound C1C(=O)CC2CC(=O)CC21 HAFQHNGZPQYKFF-UHFFFAOYSA-N 0.000 claims description 2
VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
125000002947 alkylene group Chemical group 0.000 claims description 2
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
238000011161 development Methods 0.000 claims description 2
239000006196 drop Substances 0.000 claims description 2
125000000524 functional group Chemical group 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
239000006187 pill Substances 0.000 claims description 2
SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical class CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 claims description 2
150000003254 radicals Chemical class 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims 2
229910052801 chlorine Inorganic materials 0.000 claims 2
229910052731 fluorine Inorganic materials 0.000 claims 2
229910052736 halogen Inorganic materials 0.000 claims 2
150000002367 halogens Chemical class 0.000 claims 2
229910052740 iodine Inorganic materials 0.000 claims 2
101100006960 Caenorhabditis elegans let-2 gene Proteins 0.000 claims 1
125000000732 arylene group Chemical group 0.000 claims 1
125000001033 ether group Chemical group 0.000 claims 1
238000010255 intramuscular injection Methods 0.000 claims 1
239000007927 intramuscular injection Substances 0.000 claims 1
238000010253 intravenous injection Methods 0.000 claims 1
125000000714 pyrimidinyl group Chemical group 0.000 claims 1
238000010254 subcutaneous injection Methods 0.000 claims 1
239000007929 subcutaneous injection Substances 0.000 claims 1
230000001747 exhibiting effect Effects 0.000 abstract 1
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 abstract 1
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 96
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 58
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 48
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 30
150000003141 primary amines Chemical class 0.000 description 30
238000005481 NMR spectroscopy Methods 0.000 description 28
239000012153 distilled water Substances 0.000 description 27
239000002244 precipitate Substances 0.000 description 27
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
MAWOHFOSAIXURX-UHFFFAOYSA-N cyclopentylcyclopentane Chemical group C1CCCC1C1CCCC1 MAWOHFOSAIXURX-UHFFFAOYSA-N 0.000 description 22
239000012074 organic phase Substances 0.000 description 20
239000012429 reaction media Substances 0.000 description 20
239000002904 solvent Substances 0.000 description 19
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
239000012321 sodium triacetoxyborohydride Substances 0.000 description 18
238000005160 1H NMR spectroscopy Methods 0.000 description 16
150000002978 peroxides Chemical class 0.000 description 16
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 16
239000000047 product Substances 0.000 description 16
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 13
229960003677 chloroquine Drugs 0.000 description 13
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 13
238000004452 microanalysis Methods 0.000 description 12
244000045947 parasite Species 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
230000000694 effects Effects 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 9
241000223960 Plasmodium falciparum Species 0.000 description 7
229910052938 sodium sulfate Inorganic materials 0.000 description 7
235000011152 sodium sulphate Nutrition 0.000 description 7
YNHJECZULSZAQK-UHFFFAOYSA-N tetraphenylporphyrin Chemical compound C1=CC(C(=C2C=CC(N2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3N2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 YNHJECZULSZAQK-UHFFFAOYSA-N 0.000 description 7
HXEWMTXDBOQQKO-UHFFFAOYSA-N 4,7-dichloroquinoline Chemical compound ClC1=CC=NC2=CC(Cl)=CC=C21 HXEWMTXDBOQQKO-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
239000003430 antimalarial agent Substances 0.000 description 5
229960004191 artemisinin Drugs 0.000 description 5
BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 5
229930101531 artemisinin Natural products 0.000 description 5
ZQKMYPACOGVMAD-UHFFFAOYSA-N n-(6,7a-diphenylspiro[4a,7-dihydrocyclopenta[e][1,2,4]trioxine-3,4'-cyclohexane]-1'-yl)-n'-(7-chloroquinolin-4-yl)ethane-1,2-diamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=NC2=CC(Cl)=CC=C2C=1NCCNC(CC1)CCC1(OC1C=2)OOC1(C=1C=CC=CC=1)CC=2C1=CC=CC=C1 ZQKMYPACOGVMAD-UHFFFAOYSA-N 0.000 description 5
239000000377 silicon dioxide Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
WGLLSSPDPJPLOR-UHFFFAOYSA-N 2,3-dimethylbut-2-ene Chemical compound CC(C)=C(C)C WGLLSSPDPJPLOR-UHFFFAOYSA-N 0.000 description 4
KEHNRUNQZGRQHU-UHFFFAOYSA-N 4-oxopentanal Chemical compound CC(=O)CCC=O KEHNRUNQZGRQHU-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
239000003480 eluent Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000000034 method Methods 0.000 description 4
INIWGNQYDIOLQF-UHFFFAOYSA-N n-(8a-methyl-6-propan-2-ylspiro[7,8-dihydro-4ah-1,2,4-benzotrioxine-3,4'-cyclohexane]-1'-yl)-n'-(7-chloroquinolin-4-yl)ethane-1,2-diamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O.ClC1=CC=C2C(NCCNC3CCC4(OC5C=C(CCC5(C)OO4)C(C)C)CC3)=CC=NC2=C1 INIWGNQYDIOLQF-UHFFFAOYSA-N 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
238000003756 stirring Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
YHQGMYUVUMAZJR-UHFFFAOYSA-N α-terpinene Chemical compound CC(C)C1=CC=C(C)CC1 YHQGMYUVUMAZJR-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Natural products OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
239000003708 ampul Substances 0.000 description 3
239000003638 chemical reducing agent Substances 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000003760 magnetic stirring Methods 0.000 description 3
239000012071 phase Substances 0.000 description 3
238000010992 reflux Methods 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
FTXLGZQLFOVOKK-UHFFFAOYSA-N (4-phenylcyclopenta-1,3-dien-1-yl)benzene Chemical compound C1C(C=2C=CC=CC=2)=CC=C1C1=CC=CC=C1 FTXLGZQLFOVOKK-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WSTYNZDAOAEEKG-UHFFFAOYSA-N Mayol Natural products CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(CC4(CCC33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-UHFFFAOYSA-N 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
208000035999 Recurrence Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
230000002152 alkylating effect Effects 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
150000004283 biguanides Chemical group 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
QMNFFXRFOJIOKZ-UHFFFAOYSA-N cycloguanil Chemical compound CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1 QMNFFXRFOJIOKZ-UHFFFAOYSA-N 0.000 description 2
MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
230000002498 deadly effect Effects 0.000 description 2
LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000005534 hematocrit Methods 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
VBKFNSIDWQXRES-DWXBKDDSSA-N n-[(4ar,8as)-8a-methyl-6-propan-2-ylspiro[7,8-dihydro-4ah-1,2,4-benzotrioxine-3,4'-cyclohexane]-1'-yl]-n'-(7-chloroquinolin-4-yl)ethane-1,2-diamine;hydrochloride Chemical compound Cl.ClC1=CC=C2C(NCCNC3CCC4(O[C@@H]5C=C(CC[C@]5(C)OO4)C(C)C)CC3)=CC=NC2=C1 VBKFNSIDWQXRES-DWXBKDDSSA-N 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000003071 parasitic effect Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
230000005588 protonation Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000008213 purified water Substances 0.000 description 2
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
229960004029 silicic acid Drugs 0.000 description 2
229960002920 sorbitol Drugs 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
GCMNJUJAKQGROZ-UHFFFAOYSA-N 1,2-Dihydroquinolin-2-imine Chemical compound C1=CC=CC2=NC(N)=CC=C21 GCMNJUJAKQGROZ-UHFFFAOYSA-N 0.000 description 1
GPOFSFLJOIAMSA-UHFFFAOYSA-N 1-chloro-4-ethylbenzene Chemical compound CCC1=CC=C(Cl)C=C1 GPOFSFLJOIAMSA-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical group C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 1
MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
JSHPTIGHEWEXRW-UHFFFAOYSA-N 5-hydroxypentan-2-one Chemical compound CC(=O)CCCO JSHPTIGHEWEXRW-UHFFFAOYSA-N 0.000 description 1
241000256186 Anopheles <genus> Species 0.000 description 1
235000003826 Artemisia Nutrition 0.000 description 1
235000003261 Artemisia vulgaris Nutrition 0.000 description 1
240000006891 Artemisia vulgaris Species 0.000 description 1
229940123208 Biguanide Drugs 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010026389 Gramicidin Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001081170 Homo sapiens Humanin-like 12 Proteins 0.000 description 1
102100027737 Humanin-like 12 Human genes 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
241000224016 Plasmodium Species 0.000 description 1
241000223829 Plasmodium vinckei Species 0.000 description 1
239000005700 Putrescine Substances 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
240000008254 Rosa chinensis Species 0.000 description 1
235000000664 Rosa chinensis Nutrition 0.000 description 1
230000027151 SOS response Effects 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
108010067973 Valinomycin Proteins 0.000 description 1
SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
150000005005 aminopyrimidines Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229940033495 antimalarials Drugs 0.000 description 1
229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
229960000981 artemether Drugs 0.000 description 1
235000009052 artemisia Nutrition 0.000 description 1
229960004991 artesunate Drugs 0.000 description 1
FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
235000013736 caramel Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 1
NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
FCFNRCROJUBPLU-UHFFFAOYSA-N compound M126 Natural products CC(C)C1NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC1=O FCFNRCROJUBPLU-UHFFFAOYSA-N 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229950004734 cycloguanil Drugs 0.000 description 1
DCZFGQYXRKMVFG-UHFFFAOYSA-N cyclohexane-1,4-dione Chemical compound O=C1CCC(=O)CC1 DCZFGQYXRKMVFG-UHFFFAOYSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000004205 dimethyl polysiloxane Substances 0.000 description 1
235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
238000005188 flotation Methods 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000002917 insecticide Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229960001962 mefloquine Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
231100000299 mutagenicity Toxicity 0.000 description 1
230000007886 mutagenicity Effects 0.000 description 1
FIVQKRXTOFYZCQ-UHFFFAOYSA-N n'-(7-chloroquinolin-4-yl)butane-1,4-diamine Chemical compound ClC1=CC=C2C(NCCCCN)=CC=NC2=C1 FIVQKRXTOFYZCQ-UHFFFAOYSA-N 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
230000002352 nonmutagenic effect Effects 0.000 description 1
QWVGKYWNOKOFNN-UHFFFAOYSA-N o-methyl phenol Natural products CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 1
XSHOQLFLPSMAGQ-UHFFFAOYSA-N octane-2,6-dione Chemical compound CCC(=O)CCCC(C)=O XSHOQLFLPSMAGQ-UHFFFAOYSA-N 0.000 description 1
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229940058924 other antimalarials in atc Drugs 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
150000003246 quinazolines Chemical class 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
150000007660 quinolones Chemical class 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229960001866 silicon dioxide Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000008354 sodium chloride injection Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
230000037351 starvation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
125000001174 sulfone group Chemical group 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
QQOWHRYOXYEMTL-UHFFFAOYSA-N triazin-4-amine Chemical class N=C1C=CN=NN1 QQOWHRYOXYEMTL-UHFFFAOYSA-N 0.000 description 1
210000003812 trophozoite Anatomy 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
FCFNRCROJUBPLU-DNDCDFAISA-N valinomycin Chemical compound CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O FCFNRCROJUBPLU-DNDCDFAISA-N 0.000 description 1
239000008371 vanilla flavor Substances 0.000 description 1
239000013598 vector Substances 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
- C07D323/04—Six-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Tropical Medicine & Parasitology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)

OA1200200308A 2000-04-06 2001-04-04 Molécules duales contenant un dérivé peroxydique, leur synthèse et leurs applications thérapeutiques. OA13294A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0004422A FR2807433B1 (fr)	2000-04-06	2000-04-06	Molecules duales contenant un derives peroxydique, leur synthese et leurs applications therapeutiques

Publications (1)

Publication Number	Publication Date
OA13294A true OA13294A (fr)	2007-04-13

Family

ID=8848956

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200308A OA13294A (fr)	2000-04-06	2001-04-04	Molécules duales contenant un dérivé peroxydique, leur synthèse et leurs applications thérapeutiques.

Country Status (27)

Country	Link
US (2)	US6949569B2 (is)
EP (1)	EP1268470B1 (is)
JP (1)	JP2004521855A (is)
KR (1)	KR100832047B1 (is)
CN (1)	CN1193028C (is)
AP (1)	AP1399A (is)
AR (1)	AR041773A1 (is)
AT (1)	ATE387441T1 (is)
AU (2)	AU2001248463B2 (is)
BR (1)	BR0109885A (is)
CA (1)	CA2405076C (is)
CY (1)	CY1108071T1 (is)
DE (1)	DE60132981T2 (is)
DK (1)	DK1268470T3 (is)
ES (1)	ES2302727T3 (is)
FR (1)	FR2807433B1 (is)
HU (1)	HUP0300428A2 (is)
IL (2)	IL151918A0 (is)
IS (1)	IS6579A (is)
MX (1)	MXPA02009856A (is)
MY (1)	MY128443A (is)
NO (1)	NO329526B1 (is)
NZ (1)	NZ521774A (is)
OA (1)	OA13294A (is)
PT (1)	PT1268470E (is)
WO (1)	WO2001077105A1 (is)
ZA (1)	ZA200207851B (is)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2862304A1 (fr) *	2003-11-14	2005-05-20	Centre Nat Rech Scient	Molecules duales racemiques ou achirales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques
TW200728315A (en) *	2005-12-06	2007-08-01	Nippon Chemical Ind	Phosphorus transition-metal complex, method of producing the same, and anticancer agent forming the same
FR2902100A1 (fr) *	2006-06-13	2007-12-14	Sanofi Aventis Sa	Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique
FR2924343A1 (fr) *	2007-12-04	2009-06-05	Palumed Sa	Nouvelles utilisations therapeutiques de molecules duales contenant un derive peroxydique.
EP2632886A1 (fr) *	2010-10-27	2013-09-04	Meurice R&D ASBL	Procede de fonctionnalisation de composes insatures

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2237997A1 (en) *	1995-11-16	1997-05-22	F. Hoffmann-La Roche Ag	Antimalarial quinolin derivatives

2000
- 2000-04-06 FR FR0004422A patent/FR2807433B1/fr not_active Expired - Fee Related
2001
- 2001-04-04 DE DE60132981T patent/DE60132981T2/de not_active Expired - Lifetime
- 2001-04-04 BR BR0109885-3A patent/BR0109885A/pt not_active IP Right Cessation
- 2001-04-04 IL IL15191801A patent/IL151918A0/xx unknown
- 2001-04-04 HU HU0300428A patent/HUP0300428A2/hu unknown
- 2001-04-04 MX MXPA02009856A patent/MXPA02009856A/es active IP Right Grant
- 2001-04-04 US US10/240,929 patent/US6949569B2/en not_active Expired - Fee Related
- 2001-04-04 AP APAP/P/2002/002646A patent/AP1399A/en active
- 2001-04-04 JP JP2001575578A patent/JP2004521855A/ja active Pending
- 2001-04-04 PT PT01921476T patent/PT1268470E/pt unknown
- 2001-04-04 AU AU2001248463A patent/AU2001248463B2/en not_active Ceased
- 2001-04-04 EP EP01921476A patent/EP1268470B1/fr not_active Expired - Lifetime
- 2001-04-04 CN CNB018088066A patent/CN1193028C/zh not_active Expired - Fee Related
- 2001-04-04 ES ES01921476T patent/ES2302727T3/es not_active Expired - Lifetime
- 2001-04-04 NZ NZ521774A patent/NZ521774A/en not_active IP Right Cessation
- 2001-04-04 CA CA2405076A patent/CA2405076C/fr not_active Expired - Fee Related
- 2001-04-04 AT AT01921476T patent/ATE387441T1/de active
- 2001-04-04 AU AU4846301A patent/AU4846301A/xx active Pending
- 2001-04-04 OA OA1200200308A patent/OA13294A/fr unknown
- 2001-04-04 KR KR1020027013363A patent/KR100832047B1/ko not_active Expired - Fee Related
- 2001-04-04 DK DK01921476T patent/DK1268470T3/da active
- 2001-04-04 WO PCT/FR2001/001013 patent/WO2001077105A1/fr not_active Ceased
- 2001-04-06 AR ARP010101655A patent/AR041773A1/es not_active Application Discontinuation
- 2001-04-06 MY MYPI20011659A patent/MY128443A/en unknown
2002
- 2002-09-25 IL IL151918A patent/IL151918A/en not_active IP Right Cessation
- 2002-09-30 ZA ZA200207851A patent/ZA200207851B/en unknown
- 2002-10-03 IS IS6579A patent/IS6579A/is unknown
- 2002-10-04 NO NO20024795A patent/NO329526B1/no not_active IP Right Cessation
2005
- 2005-08-04 US US11/196,979 patent/US7566710B2/en not_active Expired - Fee Related
2008
- 2008-05-26 CY CY20081100544T patent/CY1108071T1/el unknown

Also Published As

Publication number	Publication date
US6949569B2 (en)	2005-09-27
ZA200207851B (en)	2004-01-26
FR2807433B1 (fr)	2002-09-20
BR0109885A (pt)	2003-06-03
FR2807433A1 (fr)	2001-10-12
NZ521774A (en)	2005-10-28
CY1108071T1 (el)	2014-02-12
NO329526B1 (no)	2010-11-01
MXPA02009856A (es)	2004-02-26
CN1426410A (zh)	2003-06-25
IS6579A (is)	2002-10-03
CN1193028C (zh)	2005-03-16
WO2001077105A1 (fr)	2001-10-18
IL151918A (en)	2010-04-29
CA2405076A1 (fr)	2001-10-18
IL151918A0 (en)	2003-04-10
HK1056882A1 (en)	2004-03-05
EP1268470B1 (fr)	2008-02-27
EP1268470A1 (fr)	2003-01-02
DE60132981D1 (de)	2008-04-10
KR100832047B1 (ko)	2008-05-27
AR041773A1 (es)	2005-06-01
AP1399A (en)	2005-04-27
AU4846301A (en)	2001-10-23
ATE387441T1 (de)	2008-03-15
AP2002002646A0 (en)	2002-12-31
MY128443A (en)	2007-02-28
DK1268470T3 (da)	2008-06-30
NO20024795L (no)	2002-12-06
US20040038957A1 (en)	2004-02-26
NO20024795D0 (no)	2002-10-04
JP2004521855A (ja)	2004-07-22
ES2302727T3 (es)	2008-08-01
PT1268470E (pt)	2008-06-05
AU2001248463B2 (en)	2006-03-16
CA2405076C (fr)	2012-03-20
US7566710B2 (en)	2009-07-28
DE60132981T2 (de)	2009-03-19
HUP0300428A2 (hu)	2003-06-28
US20050288315A1 (en)	2005-12-29
KR20020084294A (ko)	2002-11-04

Publication	Publication Date	Title
FR2669336A1 (fr)	1992-05-22	Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
BE851310A (fr)	1977-08-10	Nouveaux derives de la tetrahydro-equinocandine b
CA2971707A1 (fr)	2016-06-30	Derives sulfoximin-phenol-amino antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines.
EP1268470B1 (fr)	2008-02-27	Molecules duales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques
NZ577311A (en)	2010-10-29	The oxalate salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one
EP0785924B1 (fr)	2000-05-03	Bis-2-aminopyridines, leur procede de preparation et leurs applications contre les parasitoses
EP1687312B1 (fr)	2010-07-14	Molecules duales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques
EP3455208B1 (en)	2020-12-16	Small molecule n-(alpha-peroxy) indole compounds and methods of use
LU83713A1 (fr)	1982-05-07	Derives de la pyrimidine,leur procede de preparation et les compositions pharmaceutiques les contenant
CA2491989C (fr)	2012-03-20	Composes a activite anti-parasitaire et medicaments les renfermant
EP1196371B1 (fr)	2005-11-02	Precurseurs de sels de bis-ammonium quaternaire et leurs applications comme prodrogues ayant une activite anti-parasitaire
EP0347305B1 (fr)	1993-05-12	[(Aryl-4-pipérazinyl-1)-2 éthoxy]-3 p-cymène, les dérivés ortho, méta, para monosubstitués ou disubstitués sur le noyau phényle dudit produit, le procédé de préparation desdits dérivés, et les médicaments contenant lesdits composés comme principe actif
CH629194A5 (fr)	1982-04-15	Amino aryl triazines-1,2,4 utilisables dans le traitement d'algies diverses.
EP0466586A1 (fr)	1992-01-15	Polyméthylène - imines disubstituées, leur procédé de préparation et les compositions pharmaceutiques les contentant
JP5457638B2 (ja)	2014-04-02	環状過酸化物誘導体
EP0082059A1 (fr)	1983-06-22	Ethers d'oximes alpha-bêta insaturés, leur procédé de préparation et leur utilisation comme médicament
WO2022244821A1 (ja)	2022-11-24	抗ウイルス活性等の生理活性を有する化合物
CA2968483A1 (fr)	2016-05-26	Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine
FR2572730A1 (fr)	1986-05-09	Nouveaux derives de l'arsenic, leur preparation et leur application, notamment comme medicaments antiparasitaires
WO2004050092A1 (fr)	2004-06-17	Utilisation de la canthin-6-one, des extraits de plantes la contenant et de ses derives dans le traitement de la maladie de chagas
FR2970966A1 (fr)	2012-08-03	Nouveaux derives de 1,5-dihydropyrrol-2-one, utiles pour le traitement du paludisme ou d'autres maladies parasitaires et fongiques
FR2637287A1 (fr)	1990-04-06	Esters de l'hydroxy-2((pyrrolidinyl-1)-2 ethoxy)-5 p-cymene, le procede de preparation desdits produits, et les medicaments contenant lesdits composes comme principe actif
FR2473521A1 (fr)	1981-07-17	2,3-dihydro-3-(1h-imidazol-1-ylmethylene)-4h-1-benzo-thiopyran-4-ones, a action antifongique et antibacterienne